fbpx

Weekly Top News – IBD – June 10, 2019

ozanimod (RPC1063) / Celgene
Ozanimod clinical trial estimate: Primary data from study 1 of P3 trial (NCT03440372) for moderate to severe Crohn’s disease in mid-2020 (Credit Suisse) – Jun 4, 2019 – A subscription to Thomson ONE is required to gain full access to report 67407582; Page no: 8; REPORT TITLE: “BMY: Conversation evolving on “Brist-ene”, but we remain on the sidelines”; AUTHOR: Divan, Vamil, et al; DATE: 05/29/2019

 

ozanimod (RPC1063) / Celgene
Ozanimod exclusivity expiry: 2034 (Credit Suisse) – Jun 4, 2019 – A subscription to Thomson ONE is required to gain full access to report 67407582; Page no: 9; REPORT TITLE: “BMY: Conversation evolving on “Brist-ene”, but we remain on the sidelines”; AUTHOR: Divan, Vamil, et al; DATE: 05/29/2019

 

Humira (adalimumab) / Eisai, AbbVie
Humira sales projection: Guidance of $21B in 2020 (Credit Suisse) – Jun 10, 2019 – A subscription to Thomson ONE is required to gain full access to report 67443417; Page no: 16; REPORT TITLE: “US Pharmaceuticals industry overview – June 2019”; AUTHOR: Divan, Vamil, et al; DATE: 06/03/2019

 

ravagalimab (ABBV-323) / AbbVie
A Study to Investigate How Well ABBV-323 Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy (clinicaltrials.gov) – Jun 7, 2019 – P2; N=40; Recruiting; Sponsor: AbbVie; N=68 –> 40

 

ozanimod (RPC1063) / Celgene
Ozanimod clinical trial estimate: Primary data from P3 trial (NCT03464097) for moderate to severe Crohn’s disease in mid-to-late 2021 (Credit Suisse) – Jun 4, 2019 – A subscription to Thomson ONE is required to gain full access to report 67407582; Page no: 8; REPORT TITLE: “BMY: Conversation evolving on “Brist-ene”, but we remain on the sidelines”; AUTHOR: Divan, Vamil, et al; DATE: 05/29/2019

No Comments

Post a Comment

Comment
Name
Email
Website